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The complete amino acid sequence of basic FGF (146 residues) from ovine pituitary glands has been estab- 
lished. This has been achieved by the sequence analysis of subnanomole amounts of the intact molecule 
and of peptides derived by enzymatic digestions with clostripain, chymotrypsin, pepsin and Staphylococcus 
aureus V8 protease. Microbore HPLC, employing 1-2 mm i.d. columns, was used to purify, concentrate 
and buffer-exchange the FGF peptides. A novel application of ion-pairing chromatography was employed 
to isolate peptides which were not retained on conventional reversed-phase systems. There is only one posi- 
tional difference between the ovine and bovine basic FGFs, but there are 3 positional differences between 
ovine and human basic FGFS. 
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1. INTRODUCTION 
Basic fibroblast growth factor (bFGF), a cat- 
ionic mitogen (pI 9.6), was first isolated by 
Gospodarowicz from bovine pituitary and brain 
[1]. bFGF has been shown in vitro to be a very po- 
tent mitogen for vascular endothelial cells and a 
wide variety of mesodermal or neuroectodermal- 
derived cells [2,3]. Although structural studies on 
bovine bFGF reveal that it is a single-chain 
polypeptide of 146 amino acids [4], the recent 
characterization of cDNA clones that encode 
human [5] and bovine [6] bFGF suggests that both 
growth factors are synthesized with amino- 
terminal 9-residue xtensions that are not found in 
the isolated forms of bovine [4,7] and human [8,9] 
bFGFs. We have now determined the complete 
Correspondence address: J. Simpson, Ludwig Institute 
for Cancer Research, PO Royal Melbourne Hospital, 
Parkville, Victoria 3050, Australia 
amino acid sequence of bFGF from ovine pituitary 
glands. 
2. MATERIALS AND METHODS 
2. I. Basic FGF isolation 
Ovine bFGF was prepared from pituitary glands 
as in [4,10]. bFGF mitogenic activity was deter- 
mined using mouse 3T3 fibroblasts as described 
[11]. 
2.2. Preparation of  S-carboxymethyl (SCM) 
bFGF 
Pure bFGF (12/zg in 420/zl) recovered from a 
Brownlee RP-300 column (30 x 2.1 mm i.d., 
Brownlee Laboratories, Santa Clara, CA) 
developed with a 0.15% (v/v) TFA/acetonitri le 
solvent system was diluted with 3 ml of 0.2 M Tris- 
HC1 buffer, pH 8.3, containing 6 M guanidine 
hydrochloride, 4 mM EDTA and 0.02% (v/v) 
Tween 20 (Pierce). Dithiothreitol was added to a 
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final concentration of 0.7 mM and reduction was 
allowed to proceed for 3 h at 45°C. A 4.3-fold 
molar excess of iodoacetic acid over total 
sulfhydryl groups was added and the incubation 
was continued at 25°C for 30 min in the dark. The 
alkylation was terminated by the addition of a 
large excess of mercaptoethanol ver iodoacetic 
acid and SCM-bFGF was purified by reversed- 
phase HPLC.  
2.3. Proteolytic digestion of basic SCM-bFGF 
SCM-bFGF (10/~g in 500/A of 36% 
acetonitrile/0.15% aqueous TFA containing 
0.02% Tween 20) was first concentrated 5-fold in 
a polypropylene tube (Eppendorf) in a Speed Vac 
concentrator (Savant) to reduce the acetonitrile 
concentration and then diluted to 1.3 ml with 
0.07 M sodium phosphate buffer, pH 7.6, contain- 
ing 8 mM dithiothreitol, 1 mM CaCI2 and 0.02% 
Tween 20. Clostripain (Boehringer), 3.3/~g, was 
added and the mixture incubated overnight at 
37°C. Prior to use clostripain was dissolved in the 
same buffer and incubated at 25°C for 2 h. Diges- 
tions with chymotrypsin (Worthington) or S. 
aureus V8 protease (Miles Co.) were performed 
overnight in 1070 (w/v) ammonium bicarbonate 
containing 0.02% Tween 20, whereas digestion 
with pepsin (Sigma) was performed in 5% formic 
acid for 65 min. 
2.4. Separation of peptides by HPLC 
Chromatography was performed using a 
Hewlett-Packard model 1090 liquid chromato- 
graph fitted with a model 1040A diode array 
detector as described in [11,12]. 
Proteolytic digests of SCM-bFGF (typically 
10/~g in 1 ml) were loaded, at a flow rate of 
1 ml/min, onto a Brownlee RP-300 column which 
had been previously equilibrated with aqueous 
0.1% (v/v) TFA. The column was developed, at a 
flow rate of 100/tl/min, with a linear 60-min gra- 
dient from 0 to 100% B, where secondary solvent 
B was 60% acetonitrile/40% aqueous 0.09% (v/v) 
TFA. Selected peak fractions were rechromato- 
graphed on the same column previously equili- 
brated with aqueous 0.9% (w/v) NaCI and eluted 
with a linear 50-min gradient from 0 to 50% B, 
where solvent B was acetonitrile. 
Non-retained peptides which eluted in the col- 
umn breakthrough fraction from the first 
chromatographic dimension were rechromato- 
graphed on an ODS-Hypersil column (Shandon 
Southern, Runcorn, England; 12 nm pore size, 
5/~m C18 packed into a 50 x 1 mm i.d. column as 
described in [11]) previously equilibrated with 
aqueous 20 mM sodium phosphate, 0.1% phos- 
phoric acid, pH 2.5 and 30 mM sodium octyl- 
sulfonate (BDH, Poole, England) (solvent A) and 
eluted, at a flow rate of 50/A/min, with a linear 
50-min gradient from 0 to 100% B, where solvent 
B was 50% acetonitrile in solvent A. In all cases, 
column temperature was maintained at 45°C and 
fractions were monitored by absorbance at 215 nm 
before being collected manually. 
2.5. Structural analysis 
Sub-50 pmol amino acid analysis of clostripain 
peptides of SCM-bFGF were performed using the 
DABS-C1 procedure described by Knecht and 
Chang [13]. Automated amino acid sequence 
analysis of protein and peptides was performed us- 
ing an Applied Biosystems equencer (model 470) 
as in [11,12]. 
3. RESULTS AND DISCUSSION 
During the early phases of this work severe sam- 
ple losses were encountered when manipulating 
HPLC-derived bFGF for proteolytic digestion 
(e.g. reduction of organic solvent concentration 
and buffer-exchange). Such losses, presumably 
due to the irreversible absorption of bFGF to the 
polypropylene HPLC collection tubes, were cir- 
cumvented by the inclusion of a nonionic detergent 
(0.02% Tween 20) during all manipulations. 
Microbore column technology [11,12] was 
employed throughout his study to trace-enrich 
protein and polypeptides in large volumes (> 1 ml) 
onto short (< 10 cm) microbore columns (1-2 mm 
i.d.) and, subsequently, recover them in high yield 
(>90%) in small volumes (20-60/A) suitable for 
microsequence analysis. 
The sequence of ovine bFGF was determined by 
automated Edman degradation of the intact pro- 
tein, and of peptides produced by clostripain, 
chymotrypsin, S. aureus V8 protease and pepsin 
digestion. The strategy by which the complete se- 
quence of ovine bFGF (146 residues) was derived 
from these data is summarized in fig.1. Much of 
the sequence was determined by analysis of the 13 
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Fig. 1. Primary structure of ovine basic FGF. Sequence data obtained from intact FGF (e), clostripain peptides (A), 
chymotryptic peptides (A), S. aureus V8 protease peptides ([]) and peptic peptides (a) are marked as indicated. 
clostripain peptides derived from SCM-bFGF. The 
clostripain digest of SCM-bFGF was fractionated 
by RP-HPLC employing a low pH TFA (pH 2.1) 
mobile-phase buffer (fig.2). Peptides CL 
1,2,7-11,13 and 14 were purified to homogeneity 
by rechromatography on the same support but 
employing unbuffered saline (0.9°7o NaC1) in the 
mobile phase (fig.3). 
The remaining clostripain peptides (CL 3-6,12) 
which were non-retained and eluted in the column 
breakthrough of fig. 1 were rechromatographed on 
ODS-Hypersil. An anionic ion-pairing reagent (oc- 
tylsulfonate) was added to the mobile phase buffer 
to enhance the chromatographic retention of these 
peptides and thereby facilitating their purification 
(fig.4). Paired-ion complexes of peptides CL 3-6 
and 12 were successfully sequenced without further 
manipulation. 
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Fig.2. HPLC separation of clostripain peptides of SCM- 
bFGF on Brownlee RP-300. Mobile phase, 0.15070 (v/v) 
aqueous TFA. 
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Fig.3. HPLC purification of clostripain peptides CL9 
and CL14. Same chromatographic conditions as in fig.2 
except hat mobile phase is 0.9°70 (w/v) aqueous NaC1. 
Automated Edman degradation of the intact 
molecule established the sequence of the first 21 
residues while the remainder of the sequence was 
established, primarily, by sequence analysis of 
clostripain peptides CL 2-14. Confirmatory se- 
quence data and information necessary to order 
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Fig.4. Ion-pair chromatography on ODS-Hypersil of 
clostripain peptides not retained on a conventional 
reversed-phase HPLC system (eluent breakthrough in
fig.Z). 
Table 1 
Summary of amino acid differences between sequences 
of ovine, bovine [5] and human [6] bFGFs 
Position in sequence 
10 112 128 
Ovine Set Ser Pro 
Bovine Gly Ser Pro 
Human Gly Thr Set 
some of the clostripain peptides were derived from 
chymotryptic, S. aureus V8 and peptic peptides 
(fig.l). Amino acid compositions of peptides CL 
7-11,13 and 14 provided confirmatory evidence of 
the sequence of these peptides. The order of 
clostripain peptides CL 3,4 and CL 8,9 was deter- 
mined by their corresponding position in bovine 
bFGF [41. 
The results presented here reveal that the 
primary structure of bFGF has been highly con- 
served between species. Only three differences are 
apparent when the amino acid sequence of ovine 
bFGF shown in fig.1 is compared with that of 
bovine bFGF [4,6] and the cDNA-deduced human 
bFGF [5]. These differences are summarized in 
table 1. The high degree of structural homology 
(97.9%) thus far observed for bFGFs implies a 
strong evolutionary selection pressure for 
maintenance of biological function and is consis- 
tent with the biological cross-reactivity across 
species of bFGF [3,9,10]. In contrast o the cDNA- 
deduced primary structures reported for bovine [6] 
and human bFGF [5], the ovine bFGF structure 
reported in fig.1 lacks a 9-residue amino acid ter- 
minal extension. This finding is in agreement with 
the automated Edman degradation of the isolated 
forms of bovine [4,7] and human bFGF [8,9] but 
differs from the bFGF-related hepatoma-derived 
growth factor from human tumor cells [14]. 
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